CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
immunologic activity of pembrolizumab plus chemotherapy when combined with various immunotherapy induction regimens as neoadjuvant therapy for triple...
Phase 2
Portland, Oregon, United States
doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...
Phase 3
Portland, Oregon, United States and 216 other locations
or ceralasertib alone in the treatment of patients with metastatic triple negative breast cancer (TNBC). Olaparib...
Phase 2
Portland, Oregon, United States
or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...
Phase 3
Portland, Oregon, United States and 160 other locations
The goal of this study is assess the safety and tolerability of the IRX-2 regimen in patients with early stage breast cancer (ESBC)-...
Phase 1
Portland, Oregon, United States
(weekly paclitaxel or capecitabine) in unresectable/metastatic triple negative breast cancer (MTNBC) patients....
Phase 1, Phase 2
Portland, Oregon, United States and 1 other location
This is a Phase II trial to assess feasibility of pembrolizumab + INBRX-106 as a chemotherapy-sparing neoadjuvant therapy. One therapeutic arm is bei...
Phase 2
Portland, Oregon, United States and 3 other locations
Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative ("triple negative") re ...
Phase 2
Portland, Oregon, United States and 3 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...
Phase 3
Portland, Oregon, United States and 508 other locations
for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...
Phase 2
Portland, Oregon, United States and 108 other locations
Clinical trials
Research sites
Resources
Legal